Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-1702
Br J Pharmacol 2005 Sep 01;1461:15-24. doi: 10.1038/sj.bjp.0706307.
Show Gene links Show Anatomy links

Evaluation of benzyltetrahydroisoquinolines as ligands for neuronal nicotinic acetylcholine receptors.

Exley R , Iturriaga-Vásquez P , Lukas RJ , Sher E , Cassels BK , Bermudez I .


???displayArticle.abstract???
Effects of derivatives of coclaurine (C), which mimic the 'eastern' or the nonquaternary halves of the alkaloids tetrandrine or d-tubocurarine, respectively, both of which are inhibitors of nicotinic acetylcholine receptors (nACh), were examined on recombinant, human alpha7, alpha4beta2 and alpha4beta4 nACh receptors expressed in Xenopus oocytes and clonal cell lines using two-electrode voltage clamping and radioligand binding techniques. In this limited series, Cs have higher affinity and are most potent at alpha4 subunit-containing-nACh receptors and least potent at homomeric alpha7 receptors, and this trend is very marked for the N-unsubstituted C and its O,O'-bisbenzyl derivative. 7-O-Benzyl-N-methylcoclaurine (BBCM) and its 12-O-methyl derivative showed the highest affinities and potencies at all three receptor subtypes, and this suggests that lipophilicity at C7 and/or C12 increases potency. Laudanosine and armepavine (A) were noncompetitive and voltage-dependent inhibitors of alpha7, alpha4beta2 or alpha4beta4 receptors, but the bulkier C7-benzylated 7BNMC (7-O-benzyl-N-methylcoclaurine) and 7B12MNMC (7-O-benzyl-N,12-O-dimethyl coclaurine) were voltage-independent, noncompetitive inhibitors of nACh receptors. Voltage-dependence was also lost on going from A to its N-ethyl analogue. These studies suggest that C derivatives may be useful tools for studies characterising the antagonist and ion channel sites on human alpha7, alpha4beta2 or alpha4beta4 nACh receptors and for revealing structure-function relationships for nACh receptor antagonists.

???displayArticle.pubmedLink??? 15980871
???displayArticle.pmcLink??? PMC1576253
???displayArticle.link??? Br J Pharmacol
???displayArticle.grants??? [+]


References [+] :
Astles, Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. 2002, Pubmed